# Survivorship Promotion In Reducing IGF-1 Trial

> **NCT02431676** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 121 (actual)

## Conditions studied

- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Colon Cancer
- Melanoma of Skin
- Endometrial Cancer
- Liver Cancer
- Pancreatic Cancer
- Rectal Cancer
- Kidney Cancer
- Other Solid Malignant Tumors

## Interventions

- **DRUG:** Metformin
- **BEHAVIORAL:** Coach Directed Behavioral Weight Loss
- **BEHAVIORAL:** Self-control weight loss

## Key facts

- **NCT ID:** NCT02431676
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2024-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431676, "Survivorship Promotion In Reducing IGF-1 Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02431676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*